The Middle EAST Pranlukast Market was valued at USD 0.15 billion in 2024 and is projected to reach USD 0.45 billion by 2034, registering a CAGR of 12.0%. This growth trajectory is underpinned by several factors, including the rising prevalence of respiratory diseases, increased awareness about asthma management, and the growing adoption of Pranlukast as a first-line treatment option. The demand...